BIO.News Newsletter

Shutdown averted—and the House Energy & Commerce Health Subcommittee advanced key legislation to rein in PBMs. Plus, two important climate reports this week highlight the need for government policy to advance existing biotech solutions. (542 words, 2 minutes, 42 seconds)

BIO’s been busy—here’s what Rachel King told global health officials about partnerships and IP, and details on BIO’s new clinical trial diversity resources. (544 words, 2 minutes, 43 seconds)

After contracting a drug-resistant infection that wouldn’t go away, a patient developed his own wound dressing—but why would he need to do this? The I am BIO Podcast explores Bradley Burnam’s story, and the state of the antimicrobials market. Plus, BIO launches a powerful new resource for early-stage biotech companies. (576 words, 2 minutes, 52 seconds)

While a potential government shutdown looms, we’re looking at exciting biotech innovations—from the world’s first vaccine for chikungunya virus, to promising treatments for a range of cardiovascular diseases. (465 words, 2 minutes, 19 seconds)

Members of Congress joined the chorus against CMS’ proposed rule on the Medicaid Drug Rebate Program, and several U.S. Representatives introduced a bill to advance SAF. Ahead of Veterans Day, we look at how biotech—including BIO’s vice chair—is recognizing and supporting veterans. (684 words, 3 minutes, 25 seconds)  

The Senate Finance Committee advanced critically important PBM transparency legislation—here’s what happened and how you can take action. Plus, BIO joined 45+ organizations in condemning the Biden administration’s recent decision on international data flows. (703 words, 3 minutes, 30 seconds)

We bring you more coverage from BIO-Europe in Munich, with what experts are saying about the proposed EU-Pharma Law. And as dengue fever spreads (including in the U.S.), biotech is providing hope in the form of promising vaccines and modified mosquitoes. (540 words, 2 minutes, 42 seconds)

BIO-Europe is happening this week in Munich, where BIO’s talking about the role of M&A in biotech innovation and investment. Plus, a new UN report details the health and climate costs of agrifood systems—but biotech already offers solutions. (580 words, 2 minutes, 54 seconds)

Starting the week with a look at how biotech is fueling the energy transition and fighting back against today’s diseases and tomorrow’s pandemics. (672 words, 3 minutes, 21 seconds)

BIO joined a letter calling for extension of critically important R&D tax credits—plus, BIO members win big at California Life Sciences’ Pantheon Awards. (500 words, 2 minutes, 30 seconds)